The Role of Oxidative Stress and MicroRNAs in Platelet Activation and the Efficacy of Antiplatelet Therapy in Acute Myocardial Infarction

Abstract

Acute myocardial infarction (AMI) remains a formidable challenge in cardiovascular medicine, necessitating effective antiplatelet therapy to mitigate adverse outcomes. Recent advances have underscored the pivotal role of oxidative stress and micro ribonucleic acids (miRNAs) in regulating platelet activation and modulating the efficacy of antiplatelet agents. This review comprehensively examines the current understanding of how oxidative stress influences platelet function and the regulatory mechanisms of miRNAs in this context. It discusses the dual role of oxidative stress in promoting and impairing platelet activity and its implications for miRNAs as critical modulators of platelet activation, including their potential utility as biomarkers and therapeutic targets. Furthermore, the interaction between oxidative stress, miRNA expression, and antiplatelet drugs is analyzed to elucidate their combined impact on AMI treatment. These insights provide potential pathways to optimize therapeutic strategies, ultimately improving patient outcomes in AMI management.

Keywords

oxidative stress - miRNA - platelet activation - antiplatelet therapy - ticagrelor - prasugrel

Publication History

Received: 27 December 2024

Accepted after revision: 16 October 2025

Article published online:
27 November 2025

• References

• 1 Xu Y, Huo Y, Toufektsian MC. et al. Activated platelets contribute importantly to myocardial reperfusion injury. Am J Physiol Heart Circ Physiol 2006; 290 (02) H692-H699
• 2 Ziegler M, Wang X, Peter K. Platelets in cardiac ischaemia/reperfusion injury: a promising therapeutic target. Cardiovasc Res 2019; 115 (07) 1178-1188
• 3 Fröhlich GM, Meier P, White SK, Yellon DM, Hausenloy DJ. Myocardial reperfusion injury: looking beyond primary PCI. Eur Heart J 2013; 34 (23) 1714-1722
• 4 Ziegler M, Alt K, Paterson BM. et al. Highly sensitive detection of minimal cardiac ischemia using positron emission tomography imaging of activated platelets. Sci Rep 2016; 6 (01) 38161
• 5 Willeit P, Zampetaki A, Dudek K. et al. Circulating microRNAs as novel biomarkers for platelet activation. Circ Res 2013; 112 (04) 595-600
• 6 Kaudewitz D, Skroblin P, Bender LH. et al. Association of microRNAs and YRNAs with platelet function. Circ Res 2016; 118 (03) 420-432
• 7 Förstermann U, Xia N, Li H. Roles of vascular oxidative stress and nitric oxide in the pathogenesis of atherosclerosis. Circ Res 2017; 120 (04) 713-735
• 8 Leo R, Praticò D, Iuliano L. et al. Platelet activation by superoxide anion and hydroxyl radicals intrinsically generated by platelets that had undergone anoxia and then reoxygenated. Circulation 1997; 95 (04) 885-891
• 9 Qiao J, Arthur JF, Gardiner EE, Andrews RK, Zeng L, Xu K. Regulation of platelet activation and thrombus formation by reactive oxygen species. Redox Biol 2018; 14: 126-130
• 10 Rakesh KS, Jagadish S, Vinayaka AC. et al. A new ibuprofen derivative inhibits platelet aggregation and ROS mediated platelet apoptosis. PLoS One 2014; 9 (09) e107182
• 11 Ye Y, Yang L, Leng M. et al. Luteolin inhibits GPVI-mediated platelet activation, oxidative stress, and thrombosis. Front Pharmacol 2023; 14: 1255069
• 12 Capra V, Bäck M, Angiolillo DJ, Cattaneo M, Sakariassen KS. Impact of vascular thromboxane prostanoid receptor activation on hemostasis, thrombosis, oxidative stress, and inflammation. J Thromb Haemost 2014; 12 (02) 126-137
• 13 Redondo PC, Jardin I, Hernández-Cruz JM, Pariente JA, Salido GM, Rosado JA. Hydrogen peroxide and peroxynitrite enhance Ca2+ mobilization and aggregation in platelets from type 2 diabetic patients. Biochem Biophys Res Commun 2005; 333 (03) 794-802
• 14 Bauer J, Ripperger A, Frantz S, Ergün S, Schwedhelm E, Benndorf RA. Pathophysiology of isoprostanes in the cardiovascular system: implications of isoprostane-mediated thromboxane A2 receptor activation. Br J Pharmacol 2014; 171 (13) 3115-3131
• 15 Bikulčienė I, Garjonytė N, Žėkas V. et al. Relationship between composition of fatty acid in platelet phospholipid membrane and markers of oxidative stress in healthy men and men after a myocardial infarction. Med Sci Monit Basic Res 2021; 27: e929634
• 16 Zhang X, Yu S, Li X. et al. Research progress on the interaction between oxidative stress and platelets: another avenue for cancer?. Pharmacol Res 2023; 191: 106777
• 17 Tyml K. Critical role for oxidative stress, platelets, and coagulation in capillary blood flow impairment in sepsis. Microcirculation 2011; 18 (02) 152-162
• 18 López-Pedrera C, Barbarroja N, Jimenez-Gomez Y, Collantes-Estevez E, Aguirre MA, Cuadrado MJ. Oxidative stress in the pathogenesis of atherothrombosis associated with anti-phospholipid syndrome and systemic lupus erythematosus: new therapeutic approaches. Rheumatology (Oxford) 2016; 55 (12) 2096-2108
• 19 Beura SK, Dhapola R, Panigrahi AR, Yadav P, Reddy DH, Singh SK. Redefining oxidative stress in Alzheimer's disease: targeting platelet reactive oxygen species for novel therapeutic options. Life Sci 2022; 306: 120855
• 20 Villalpando-Rodriguez GE, Gibson SB. Reactive oxygen species (ROS) regulates different types of cell death by acting as a rheostat. Oxid Med Cell Longev 2021; 2021: 9912436
• 21 Fuentes E, Gibbins JM, Holbrook LM, Palomo I. NADPH oxidase 2 (NOX2): a key target of oxidative stress-mediated platelet activation and thrombosis. Trends Cardiovasc Med 2018; 28 (07) 429-434
• 22 Krötz F, Sohn HY, Gloe T. et al. NAD(P)H oxidase-dependent platelet superoxide anion release increases platelet recruitment. Blood 2002; 100 (03) 917-924
• 23 Basili S, Pignatelli P, Tanzilli G. et al. Anoxia-reoxygenation enhances platelet thromboxane A2 production via reactive oxygen species-generated NOX2: effect in patients undergoing elective percutaneous coronary intervention. Arterioscler Thromb Vasc Biol 2011; 31 (08) 1766-1771
• 24 Looi YH, Grieve DJ, Siva A. et al. Involvement of Nox2 NADPH oxidase in adverse cardiac remodeling after myocardial infarction. Hypertension 2008; 51 (02) 319-325
• 25 Raghuvanshi R, Kaul A, Bhakuni P, Mishra A, Misra MK. Xanthine oxidase as a marker of myocardial infarction. Indian J Clin Biochem 2007; 22 (02) 90-92
• 26 Charlat MI, O'Neill PG, Egan JM. et al. Evidence for a pathogenetic role of xanthine oxidase in the “stunned” myocardium. Am J Physiol 1987; 252 (3 Pt 2): H566-H577
• 27 Lambert AJ, Brand MD. Superoxide production by NADH:ubiquinone oxidoreductase (complex I) depends on the pH gradient across the mitochondrial inner membrane. Biochem J 2004; 382 (Pt 2): 511-517
• 28 Leytin V. Apoptosis in the anucleate platelet. Blood Rev 2012; 26 (02) 51-63
• 29 McArthur K, Chappaz S, Kile BT. Apoptosis in megakaryocytes and platelets: the life and death of a lineage. Blood 2018; 131 (06) 605-610
• 30 Choo HJ, Saafir TB, Mkumba L, Wagner MB, Jobe SM. Mitochondrial calcium and reactive oxygen species regulate agonist-initiated platelet phosphatidylserine exposure. Arterioscler Thromb Vasc Biol 2012; 32 (12) 2946-2955
• 31 Ricci JE, Gottlieb RA, Green DR. Caspase-mediated loss of mitochondrial function and generation of reactive oxygen species during apoptosis. J Cell Biol 2003; 160 (01) 65-75
• 32 Stockwell BR, Friedmann Angeli JP, Bayir H. et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell 2017; 171 (02) 273-285
• 33 Liu JP, Cen SY, Xue Z. et al. A class of disulfide compounds suppresses ferroptosis by stabilizing GPX4. ACS Chem Biol 2022; 17 (12) 3389-3406
• 34 Miyamoto HD, Ikeda M, Ide T. et al. Iron overload via heme degradation in the endoplasmic reticulum triggers ferroptosis in myocardial ischemia-reperfusion injury. JACC Basic Transl Sci 2022; 7 (08) 800-819
• 35 NaveenKumar SK, Hemshekhar M, Kemparaju K, Girish KS. Hemin-induced platelet activation and ferroptosis is mediated through ROS-driven proteasomal activity and inflammasome activation: protection by melatonin. Biochim Biophys Acta Mol Basis Dis 2019; 1865 (09) 2303-2316
• 36 Miao S, Zhang Q, Ding W. et al. Platelet internalization mediates ferroptosis in myocardial infarction. Arterioscler Thromb Vasc Biol 2023; 43 (02) 218-230
• 37 Masselli E, Pozzi G, Vaccarezza M. et al. ROS in platelet biology: functional aspects and methodological insights. Int J Mol Sci 2020; 21 (14) 4866
• 38 Scioli MG, Storti G, D'Amico F. et al. Oxidative stress and new pathogenetic mechanisms in endothelial dysfunction: potential diagnostic biomarkers and therapeutic targets. J Clin Med 2020; 9 (06) 1995
• 39 Walsh TG, Poole AW. Platelets protect cardiomyocytes from ischaemic damage. TH Open 2017; 1 (01) e24-e32
• 40 Yang BC, Mehta JL. Platelet-derived adenosine contributes to the cardioprotective effects of platelets against ischemia-reperfusion injury in isolated rat heart. J Cardiovasc Pharmacol 1994; 24 (05) 779-785
• 41 Rath D, Chatterjee M, Müller I. et al. Platelet expression of transforming growth factor beta 1 is enhanced and associated with cardiovascular prognosis in patients with acute coronary syndrome. Atherosclerosis 2014; 237 (02) 754-759
• 42 Vito CD, Hadi LA, Navone SE. et al. Platelet-derived sphingosine-1-phosphate and inflammation: from basic mechanisms to clinical implications. Platelets 2016; 27 (05) 393-401
• 43 Geisler T, Fekecs L, Wurster T. et al. Association of platelet-SDF-1 with hemodynamic function and infarct size using cardiac MR in patients with AMI. Eur J Radiol 2012; 81 (04) e486-e490
• 44 Chacko BK, Kramer PA, Ravi S. et al. Methods for defining distinct bioenergetic profiles in platelets, lymphocytes, monocytes, and neutrophils, and the oxidative burst from human blood. Lab Invest 2013; 93 (06) 690-700
• 45 Tamura N, Goto S, Yokota H, Goto S. Contributing role of mitochondrial energy metabolism on platelet adhesion, activation and thrombus formation under blood flow conditions. Platelets 2022; 33 (07) 1083-1089
• 46 Miwa S, Brand MD. Mitochondrial matrix reactive oxygen species production is very sensitive to mild uncoupling. Biochem Soc Trans 2003; 31 (Pt 6): 1300-1301
• 47 Bouillaud F, Alves-Guerra MC, Ricquier D. UCPs, at the interface between bioenergetics and metabolism. Biochim Biophys Acta 2016; 1863 (10) 2443-2456
• 48 Bround MJ, Bers DM, Molkentin JDA. A 20/20 view of ANT function in mitochondrial biology and necrotic cell death. J Mol Cell Cardiol 2020; 144: A3-A13
• 49 Shiva S, Novelli EM, Bullock GC, Kenny E, Hill G, Corey CG. Mitochondrial uncoupling protein 2 is present in human platelets and regulates platelet activation. Blood 2014; 124 (21) 4147
• 50 Demine S, Renard P, Arnould T. Mitochondrial uncoupling: a key controller of biological processes in physiology and diseases. Cells 2019; 8 (08) 795
• 51 Zhang W, Chen C, Wang J, Liu L, He Y, Chen Q. Mitophagy in cardiomyocytes and in platelets: a major mechanism of cardioprotection against ischemia/reperfusion injury. Physiology (Bethesda) 2018; 33 (02) 86-98
• 52 Zhang W, Ren H, Xu C. et al. Hypoxic mitophagy regulates mitochondrial quality and platelet activation and determines severity of I/R heart injury. eLife 2016; 5: e21407
• 53 Szilágyi B, Fejes Z, Rusznyák Á. et al. Platelet microparticles enriched in miR-223 reduce ICAM-1-dependent vascular inflammation in septic conditions. Front Physiol 2021; 12: 658524
• 54 Kloosterman WP, Plasterk RHA. The diverse functions of microRNAs in animal development and disease. Dev Cell 2006; 11 (04) 441-450
• 55 Li J, Tan M, Xiang Q, Zhou Z, Yan H. Thrombin-activated platelet-derived exosomes regulate endothelial cell expression of ICAM-1 via microRNA-223 during the thrombosis-inflammation response. Thromb Res 2017; 154: 96-105
• 56 Weyrich AS, Lindemann S, Tolley ND. et al. Change in protein phenotype without a nucleus: translational control in platelets. Semin Thromb Hemost 2004; 30 (04) 491-498
• 57 Kondkar AA, Bray MS, Leal SM. et al. VAMP8/endobrevin is overexpressed in hyperreactive human platelets: suggested role for platelet microRNA. J Thromb Haemost 2010; 8 (02) 369-378
• 58 Cimmino G, Tarallo R, Nassa G. et al. Activating stimuli induce platelet microRNA modulation and proteome reorganisation. Thromb Haemost 2015; 114 (01) 96-108
• 59 Engedal N, Žerovnik E, Rudov A. et al. From oxidative stress damage to pathways, networks, and autophagy via microRNAs. Oxid Med Cell Longev 2018; 2018: 4968321
• 60 Climent M, Viggiani G, Chen YW, Coulis G, Castaldi A. MicroRNA and ROS crosstalk in cardiac and pulmonary diseases. Int J Mol Sci 2020; 21 (12) 4370
• 61 Kura B, Bacova BS, Kalocayova B, Sykora M, Slezak J. Oxidative stress-responsive microRNAs in heart injury. Int J Mol Sci 2020; 21 (01) 358
• 62 Schütte JP, Manke MC, Hemmen K. et al. Platelet-derived microRNAs regulate cardiac remodeling after myocardial ischemia. Circ Res 2023; 132 (07) e96-e113
• 63 Olejniczak M, Kotowska-Zimmer A, Krzyzosiak W. Stress-induced changes in miRNA biogenesis and functioning. Cell Mol Life Sci 2018; 75 (02) 177-191
• 64 Kumari S, Chaurasia SN, Nayak MK, Mallick RL, Dash D. Sirtuin inhibition induces apoptosis-like changes in platelets and thrombocytopenia. J Biol Chem 2015; 290 (19) 12290-12299
• 65 Spinelli SL, Casey AE, Pollock SJ. et al. Platelets and megakaryocytes contain functional nuclear factor-kappaB. Arterioscler Thromb Vasc Biol 2010; 30 (03) 591-598
• 66 Pu M, Chen J, Tao Z. et al. Regulatory network of miRNA on its target: coordination between transcriptional and post-transcriptional regulation of gene expression. Cell Mol Life Sci 2019; 76 (03) 441-451
• 67 Wiesen JL, Tomasi TB. Dicer is regulated by cellular stresses and interferons. Mol Immunol 2009; 46 (06) 1222-1228
• 68 Kozakowska M, Ciesla M, Stefanska A. et al. Heme oxygenase-1 inhibits myoblast differentiation by targeting myomirs. Antioxid Redox Signal 2012; 16 (02) 113-127
• 69 Quévillon Huberdeau M, Zeitler DM, Hauptmann J. et al. Phosphorylation of Argonaute proteins affects mRNA binding and is essential for microRNA-guided gene silencing in vivo . EMBO J 2017; 36 (14) 2088-2106
• 70 Lazar S. The Roles of AGO2 in Megakaryopoiesis, Protein Expression, and Platelet Reactivity [Ph.D. dissertation]. Temple University, PA; 2022. . ProQuest
• 71 Cheng X, Ku CH, Siow RCM. Regulation of the Nrf2 antioxidant pathway by microRNAs: new players in micromanaging redox homeostasis. Free Radic Biol Med 2013; 64: 4-11
• 72 Fierro-Fernández M, Miguel V, Lamas S. Role of redoximiRs in fibrogenesis. Redox Biol 2016; 7: 58-67
• 73 Zhang J, Cai W, Fan Z. et al. MicroRNA-24 inhibits the oxidative stress induced by vascular injury by activating the Nrf2/Ho-1 signaling pathway. Atherosclerosis 2019; 290: 9-18
• 74 Li J, Yang C, Wang Y. miR–126 overexpression attenuates oxygen–glucose deprivation/reperfusion injury by inhibiting oxidative stress and inflammatory response via the activation of SIRT1/Nrf2 signaling pathway in human umbilical vein endothelial cells. Mol Med Rep 2021; 23 (02) 165
• 75 Laffont B, Corduan A, Plé H. et al. Activated platelets can deliver mRNA regulatory Ago2•microRNA complexes to endothelial cells via microparticles. Blood 2013; 122 (02) 253-261
• 76 Landry P, Plante I, Ouellet DL, Perron MP, Rousseau G, Provost P. Existence of a microRNA pathway in anucleate platelets. Nat Struct Mol Biol 2009; 16 (09) 961-966
• 77 O'Connell RM, Zhao JL, Rao DS. MicroRNA function in myeloid biology. Blood 2011; 118 (11) 2960-2969
• 78 de Boer HC, van Solingen C, Prins J. et al. Aspirin treatment hampers the use of plasma microRNA-126 as a biomarker for the progression of vascular disease. Eur Heart J 2013; 34 (44) 3451-3457
• 79 Zhang LJ, Hu YX, Huang RZ. et al. Intraplatelet miRNA-126 regulates thrombosis and its reduction contributes to platelet inhibition. Cardiovasc Res 2024; 120 (13) 1622-1635
• 80 Chen J, Cui C, Yang X. et al. MiR-126 affects brain-heart interaction after cerebral ischemic stroke. Transl Stroke Res 2017; 8 (04) 374-385
• 81 Yang Q, Yang K, Li A. microRNA-21 protects against ischemia-reperfusion and hypoxia-reperfusion-induced cardiocyte apoptosis via the phosphatase and tensin homolog/Akt-dependent mechanism. Mol Med Rep 2014; 9 (06) 2213-2220
• 82 Gu GL, Xu XL, Sun XT. et al. Cardioprotective effect of microRNA-21 in murine myocardial infarction. Cardiovasc Ther 2015; 33 (03) 109-117
• 83 Barwari T, Eminaga S, Mayr U. et al. Inhibition of profibrotic microRNA-21 affects platelets and their releasate. JCI Insight 2018; 3 (21) e123335
• 84 Wei C, Li L, Kim IK, Sun P, Gupta S. NF-κB mediated miR-21 regulation in cardiomyocytes apoptosis under oxidative stress. Free Radic Res 2014; 48 (03) 282-291
• 85 Xiao X, Lu Z, Lin V. et al. MicroRNA miR-24-3p reduces apoptosis and regulates Keap1-Nrf2 pathway in mouse cardiomyocytes responding to ischemia/reperfusion injury. Oxid Med Cell Longev 2018; 2018: 7042105
• 86 Zampetaki A, Willeit P, Tilling L. et al. Prospective study on circulating microRNAs and risk of myocardial infarction. J Am Coll Cardiol 2012; 60 (04) 290-299
• 87 Karolina DS, Tavintharan S, Armugam A. et al. Circulating miRNA profiles in patients with metabolic syndrome. J Clin Endocrinol Metab 2012; 97 (12) E2271-E2276
• 88 Zampetaki A, Kiechl S, Drozdov I. et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res 2010; 107 (06) 810-817
• 89 Schulte C, Molz S, Appelbaum S. et al. miRNA-197 and miRNA-223 predict cardiovascular death in a cohort of patients with symptomatic coronary artery disease. PLoS One 2015; 10 (12) e0145930
• 90 Chen ZM, Jiang LX, Chen YP. et al; COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366 (9497) 1607-1621
• 91 Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005; 45 (02) 246-251
• 92 Wallentin L, Becker RC, Budaj A. et al; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361 (11) 1045-1057
• 93 Wiviott SD, Braunwald E, McCabe CH. et al; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357 (20) 2001-2015
• 94 Krötz F, Sohn HY, Pohl U. Reactive oxygen species: players in the platelet game. Arterioscler Thromb Vasc Biol 2004; 24 (11) 1988-1996
• 95 Cipollone F, Ciabattoni G, Patrignani P. et al. Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. Circulation 2000; 102 (09) 1007-1013
• 96 Bhattacharyya S, Sinha K, Sil PC. Cytochrome P450s: mechanisms and biological implications in drug metabolism and its interaction with oxidative stress. Curr Drug Metab 2014; 15 (07) 719-742
• 97 Caruso R, Rocchiccioli S, Gori AM. et al. Inflammatory and antioxidant pattern unbalance in “clopidogrel-resistant” patients during acute coronary syndrome. Mediators Inflamm 2015; 2015: 710123
• 98 Geisler T, Anders N, Paterok M. et al. Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation. Diabetes Care 2007; 30 (02) 372-374
• 99 Prasad K, Lee P. Suppression of oxidative stress as a mechanism of reduction of hypercholesterolemic atherosclerosis by aspirin. J Cardiovasc Pharmacol Ther 2003; 8 (01) 61-69
• 100 Grosser N, Abate A, Oberle S. et al. Heme oxygenase-1 induction may explain the antioxidant profile of aspirin. Biochem Biophys Res Commun 2003; 308 (04) 956-960
• 101 Frydrychowski P, Michałek M, Bil-Lula I. et al. Cardioprotective effect of acetylsalicylic acid in the myocardial ischemia-reperfusion model on oxidative stress markers levels in heart muscle and serum. Antioxidants 2022; 11 (08) 1432
• 102 Adamski P, Koziński M, Ostrowska M. et al. Overview of pleiotropic effects of platelet P2Y12 receptor inhibitors - PubMed. Thromb Haemost 2014; 112 (02) 224-242
• 103 Nanhwan MK, Ling S, Kodakandla M, Nylander S, Ye Y, Birnbaum Y. Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect. Arterioscler Thromb Vasc Biol 2014; 34 (09) 2078-2085
• 104 Parker WAE, Schulte C, Barwari T. et al. Aspirin, clopidogrel and prasugrel monotherapy in patients with type 2 diabetes mellitus: a double-blind randomised controlled trial of the effects on thrombotic markers and microRNA levels. Cardiovasc Diabetol 2020; 19 (01) 3
• 105 Gumiężna K, Bednarek A, Sygitowicz G. et al. Platelet microRNAs as potential novel biomarkers for antiplatelet therapy with P2Y₁₂ inhibitors and their association with platelet function. J Clin Med 2023; 13 (01) 63
• 106 Carino A, De Rosa S, Sorrentino S. et al. Modulation of circulating microRNAs levels during the switch from clopidogrel to ticagrelor. BioMed Res Int 2016; 2016: 3968206
• 107 Jäger B, Stojkovic S, Haller PM. et al. Course of platelet miRNAs after cessation of P2Y12 antagonists. Eur J Clin Invest 2019; 49 (08) e13149
• 108 Byrne RA, Rossello X, Coughlan JJ. et al; ESC Scientific Document Group. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J 2023; 44 (38) 3720-3826
• 109 Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol 2005; 45 (08) 1157-1164
• 110 Paniccia R, Priora R, Liotta AA, Abbate R. Platelet function tests: a comparative review. Vasc Health Risk Manag 2015; 11: 133-148
• 111 Roule V, Ardouin P, Repessé Y. et al. Point of care tests VerifyNow P2Y12 and INNOVANCE PFA P2Y compared to light transmittance aggregometry after fibrinolysis. Clin Appl Thromb Hemost 2018; 24 (07) 1109-1116
• 112 Sun J, Yang GH, Liu JX. et al. Discordance between VASP phosphorylation and platelet aggregation in defining high on-clopidogrel platelet reactivity after ST-segment elevation myocardial infarction. Clin Appl Thromb Hemost 2018; 24 (01) 47-54
• 113 Köhler D, Straub A, Weissmüller T. et al. Phosphorylation of vasodilator-stimulated phosphoprotein prevents platelet-neutrophil complex formation and dampens myocardial ischemia-reperfusion injury. Circulation 2011; 123 (22) 2579-2590
• 114 Dias JD, Pottgiesser T, Hartmann J, Duerschmied D, Bode C, Achneck HE. Comparison of three common whole blood platelet function tests for in vitro P2Y12 induced platelet inhibition. J Thromb Thrombolysis 2020; 50 (01) 135-143
• 115 Yun SH, Sim EH, Goh RY, Park JI, Han JY. Platelet activation: the mechanisms and potential biomarkers. BioMed Res Int 2016; 2016: 9060143
• 116 Pluta K, Porębska K, Urbanowicz T. et al. Platelet-leucocyte aggregates as novel biomarkers in cardiovascular diseases. Biology (Basel) 2022; 11 (02) 224
• 117 Serebruany VL, Midei MG, Meilman H, Malinin AI, Lowry DR. Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study. Postgrad Med J 2006; 82 (968) 404-410
• 118 Li L, Li S, Wu M. et al. Early diagnostic value of circulating microRNAs in patients with suspected acute myocardial infarction. J Cell Physiol 2019; 234 (08) 13649-13658
• 119 Wang Q, Liu B, Wang Y, Bai B, Yu T, Chu XM. The biomarkers of key miRNAs and target genes associated with acute myocardial infarction. PeerJ 2020; 8: e9129
• 120 Hromadka M, Motovska Z, Hlinomaz O. et al. MiR-126-3p and MiR-223-3p as biomarkers for prediction of thrombotic risk in patients with acute myocardial infarction and primary angioplasty. J Pers Med 2021; 11 (06) 508
• 121 Yu XY, Chen JY, Zheng ZW. et al. Plasma miR-126 as a potential marker predicting major adverse cardiac events in dual antiplatelet-treated patients after percutaneous coronary intervention. EuroIntervention 2013; 9 (05) 546-554
• 122 Salic K, De Windt LJ. MicroRNAs as biomarkers for myocardial infarction. Curr Atheroscler Rep 2012; 14 (03) 193-200
• 123 Krammer TL, Mayr M, Hackl M. microRNAs as promising biomarkers of platelet activity in antiplatelet therapy monitoring. Int J Mol Sci 2020; 21 (10) 3477
• 124 Fejes Z, Póliska S, Czimmerer Z. et al. Hyperglycaemia suppresses microRNA expression in platelets to increase P2RY12 and SELP levels in type 2 diabetes mellitus. Thromb Haemost 2017; 117 (03) 529-542
• 125 Meng Q, Huo X, Sun H, Wang H, Luan Z, Wang S. miR-223 regulates myocardial ischemia-reperfusion damage via targeting NLRP3 in vitro and in vivo. Naunyn Schmiedebergs Arch Pharmacol 2021; 394 (11) 2187-2195
• 126 Duan S, Wang C, Xu X. et al. Peripheral serum exosomes isolated from patients with acute myocardial infarction promote endothelial cell angiogenesis via the miR-126-3p/TSC1/mTORC1/HIF-1α pathway. Int J Nanomedicine 2022; 17: 1577-1592
• 127 Jayawardena E, Medzikovic L, Ruffenach G, Eghbali M. Role of miRNA-1 and miRNA-21 in acute myocardial ischemia-reperfusion injury and their potential as therapeutic strategy. Int J Mol Sci 2022; 23 (03) 1512
• 128 Gu H, Liu Z, Li Y. et al. Serum-derived extracellular vesicles protect against acute myocardial infarction by regulating miR-21/PDCD4 signaling pathway. Front Physiol 2018; 9: 348
• 129 Oerlemans MIFJ, Mosterd A, Dekker MS. et al. Early assessment of acute coronary syndromes in the emergency department: the potential diagnostic value of circulating microRNAs. EMBO Mol Med 2012; 4 (11) 1176-1185
• 130 Xu L, Tian L, Yan Z, Wang J, Xue T, Sun Q. Diagnostic and prognostic value of miR-486-5p, miR-451a, miR-21-5p and monocyte to high-density lipoprotein cholesterol ratio in patients with acute myocardial infarction. Heart Vessels 2023; 38 (03) 318-331
• 131 Li C, Fang M, Lin Z, Wang W, Li X. MicroRNA-24 protects against myocardial ischemia-reperfusion injury via the NF-κB/TNF-α pathway. Exp Ther Med 2021; 22 (05) 1288
• 132 Fiedler J, Jazbutyte V, Kirchmaier BC. et al. MicroRNA-24 regulates vascularity after myocardial infarction. Circulation 2011; 124 (06) 720-730
• 133 Wang J, Huang W, Xu R. et al. MicroRNA-24 regulates cardiac fibrosis after myocardial infarction. J Cell Mol Med 2012; 16 (09) 2150-2160
• 134 Cheng J, Liu Q, Hu N. et al. Downregulation of hsa_circ_0068087 ameliorates TLR4/NF-κB/NLRP3 inflammasome-mediated inflammation and endothelial cell dysfunction in high glucose conditioned by sponging miR-197. Gene 2019; 709: 1-7
• 135 Bian H, Shan H, Chen T. Resveratrol ameliorates hypoxia/ischemia-induced brain injury in the neonatal rat via the miR-96/Bax axis. Childs Nerv Syst 2017; 33 (11) 1937-1945
• 136 Jin F, Jin L, Wei B. et al. miR-96-5p alleviates cerebral ischemia-reperfusion injury in mice by inhibiting pyroptosis via downregulating caspase 1. Exp Neurol 2024; 374: 114676
• 137 Wang J, Dong G, Chi W, Nie Y. MiR-96 promotes myocardial infarction-induced apoptosis by targeting XIAP. Biomed Pharmacother 2021; 138: 111208
• 138 Desjarlais M, Dussault S, Dhahri W, Mathieu R, Rivard A. MicroRNA-150 modulates ischemia-induced neovascularization in atherosclerotic conditions. Arterioscler Thromb Vasc Biol 2017; 37 (05) 900-908
• 139 Zhu XG, Zhang TN, Wen R, Liu CF. Overexpression of miR-150-5p alleviates apoptosis in sepsis-induced myocardial depression. BioMed Res Int 2020; 2020: 3023186
• 140 Scrutinio D, Conserva F, Passantino A, Iacoviello M, Lagioia R, Gesualdo L. Circulating microRNA-150-5p as a novel biomarker for advanced heart failure: a genome-wide prospective study. J Heart Lung Transplant 2017; 36 (06) 616-624
• 141 Li H, Zhang P, Li F. et al. Plasma miR-22-5p, miR-132-5p, and miR-150-3p are associated with acute myocardial infarction. BioMed Res Int 2019; 2019: 5012648
• 142 Li S, Guo LZ, Kim MH, Han JY, Serebruany V. Platelet microRNA for predicting acute myocardial infarction. J Thromb Thrombolysis 2017; 44 (04) 556-564
• 143 Qin Y, Wang G, Peng Z. MicroRNA-191-5p diminished sepsis-induced acute kidney injury through targeting oxidative stress responsive 1 in rat models. Biosci Rep 2019; 39 (08) BSR20190548
• 144 Du K, Zhao C, Wang L. et al. MiR-191 inhibit angiogenesis after acute ischemic stroke targeting VEZF1. Aging (Albany NY) 2019; 11 (09) 2762-2786
• 145 Li C, Chen X, Huang J, Sun Q, Wang L. Clinical impact of circulating miR-26a, miR-191, and miR-208b in plasma of patients with acute myocardial infarction. Eur J Med Res 2015; 20 (01) 58
• 146 Kranzhofer R, Ruef J. Aspirin resistance in coronary artery disease is correlated to elevated markers for oxidative stress but not to the expression of cyclooxygenase (COX) 1/2, a novel COX-1 polymorphism or the PlA(1/2) polymorphism. Platelets 2006; 17 (03) 163-169
• 147 Simpson SH, Abdelmoneim AS, Omran D, Featherstone TR. Prevalence of high on-treatment platelet reactivity in diabetic patients treated with aspirin. Am J Med 2014; 127 (01) 95.e1-95.e9
• 148 Li WJ, Zhang HY, Miao CL. et al. Cigarette smoking inhibits the anti-platelet activity of aspirin in patients with coronary heart disease. Chin Med J (Engl) 2011; 124 (10) 1569-1572
• 149 Khudair LK, Al-Ani AW. Correlation between oxidative stress and clopidogrel drug in Iraqi patients with coronary artery disease. Int J Health Sci (Qassim) 2022; 6 (S9): 1164-1174
• 150 Kanko M, Maral H, Akbas MH. et al. Protective effects of clopidogrel on oxidant damage in a rat model of acute ischemia. Tohoku J Exp Med 2005; 205 (02) 133-139
• 151 Rudolph TK, Fuchs A, Klinke A. et al. Prasugrel as opposed to clopidogrel improves endothelial nitric oxide bioavailability and reduces platelet-leukocyte interaction in patients with unstable angina pectoris: a randomized controlled trial. Int J Cardiol 2017; 248: 7-13
• 152 Fakhri YA, Al-Ani AW. Association of superoxide dismutase with ticagrelor treatment in patients with peripheral arterial disease. Iraqi J Sci 2025; 66 (05) 1812-1823
• 153 El-Mokadem BM, El-Abhar HS, Abdallah DM, Awad AS, Soubh AA. Epac-1/Rap-1 signaling pathway orchestrates the reno-therapeutic effect of ticagrelor against renal ischemia/reperfusion model. Biomed Pharmacother 2021; 139: 111488
• 154 Adamski P, Koziński M, Ostrowska M. et al. Overview of pleiotropic effects of platelet P2Y12 receptor inhibitors. Thromb Haemost 2014; 112 (02) 224-242
• 155 Liu J, Qin L, Wang Z. et al. Platelet-derived miRNAs as determinants of the antiplatelet response in clopidogrel-treated patients with ACS. Thromb Res 2020; 186: 71-74
• 156 Shi R, Zhou X, Ji WJ. et al. The emerging role of miR-223 in platelet reactivity: implications in antiplatelet therapy. BioMed Res Int 2015; 2015: 981841
• 157 Garcia A, Dunoyer-Geindre S, Zapilko V, Nolli S, Reny JL, Fontana P. Functional validation of microRNA-126-3p as a platelet reactivity regulator using human haematopoietic stem cells. Thromb Haemost 2019; 119 (02) 254-263
• 158 Peng L, Liu J, Qin L. et al. Interaction between platelet-derived microRNAs and CYP2C19*2 genotype on clopidogrel antiplatelet responsiveness in patients with ACS. Thromb Res 2017; 157: 97-102
• 159 Lin S, Xu X, Hu H. et al. The expression profile of platelet-derived miRNA in coronary artery disease patients with clopidogrel resistance. Pharmacol Res Perspect 2021; 9 (02) e00751